Osteoarthritis

Osteoarthritis Therapeutics Market to grow by USD 3.96 billion from 2022-2027, North America to account for 32% of market growth - Technavio

Retrieved on: 
Wednesday, January 17, 2024
Obesity, X-ray, Regenerative medicine, Osteoarthritis, Risk, Therapy, Research, MRI, Pressure, ROW, Analgesic, NSAID, Health, Pain management, FREE, Nonsteroidal anti-inflammatory drug, Disease, Pfizer, Eli Lilly, Nonsteroidal, Drug development, USD, Ulcer, Burns, Biomarker, DSM-IV codes, Inflammation, Rheumatology, Ageing, Growth, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The osteoarthritis therapeutics market size is expected to grow by USD 3.96 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The osteoarthritis therapeutics market size is expected to grow by USD 3.96 billion from 2022 to 2027.
  • North America will contribute 32% to the growth of the global market during the forecast period.
  • Such diagnostic advancements not only aid in understanding drug effectiveness but also drive growth in the osteoarthritis therapeutics market.
  • Growth of the osteoarthritis therapeutics market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of osteoarthritis therapeutics market vendors.

First Patient Enrolled in Merit Medical’s MOTION Study

Retrieved on: 
Tuesday, January 16, 2024
Injection, IDE, Osteoarthritis, Patient, Risk, Hypervascularity, Evidence-based medicine, MD, Knee, Incidence, Microparticle, FDA, Pain, Inflammation, Blood, MMSI, GAE, Prevalence, Pharmaceutical industry

Under this designation, Embosphere Microspheres received priority review by the FDA, which allowed for accelerated review and development of the MOTION study protocol.

Key Points: 
  • Under this designation, Embosphere Microspheres received priority review by the FDA, which allowed for accelerated review and development of the MOTION study protocol.
  • In conducting the study, Merit intends to randomize patients 1:1 to receive either GAE using Embosphere Microspheres or intra-articular corticosteroid injections.
  • The study is structured to evaluate primary safety and effectiveness of Embosphere Microspheres at 6 months with continued patient follow up through 24 months.
  • “The commencement of this randomized controlled study is a testament to our commitment to evidence-based medicine and patient-centric care,” said Sandeep Bagla, MD, Co-Global Principal Investigator of the MOTION study.

2024 Feather in Her Cap and High Flyer Award Winners Named for Outstanding Achievements in Animal Health Industry

Retrieved on: 
Tuesday, January 16, 2024
Philanthropy, Health, Consumer, Women, Foundation, Veterinary, Animal Health, Woman, Osteoarthritis, Therapy, Frunevetmab, Multimedia, Female, Intellectual disability, University, Engagement, Mentorship, Dog, Pharmaceutics, Elanco, Veteran, Cat, DVM, Boehringer Ingelheim, ELAN, Doctor of Philosophy, Veterinary medicine, Highflyer, Feather, Marketing, Formulation, Inclusion, Education, Management

The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.

Key Points: 
  • The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.
  • Andrea J. Gonzales Ph.D., vice president of Global Companion Animal Therapeutics at Zoetis, Inc., (NYSE: ZTS) was awarded the 2024 Feather in Her Cap award and Katharina Bohnenblust Ph.D., senior director, head of Formulation Development at Elanco Animal Health (NYSE: ELAN) was this year’s recipient of the 2024 High Flyer award.
  • Each year, the Feather in Her Cap award winner chooses an animal-related non-profit organization to receive a $5,000 donation.
  • The nomination process will reopen in Q3 of 2024 to celebrate more outstanding women in Animal Health in 2025.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT VETERINARY MEETING AND EXPO CONFERENCE IN ORLANDO, FLORIDA

Retrieved on: 
Tuesday, January 9, 2024
Osteoarthritis, Animal, VMX, Orange County Convention Center, Joint, Arthralgia, Conference, Therapy, Veterinary medicine

The Company’s management is excited to meet with many of the 15,000+ participants to introduce its lead product, Spryng™ with OsteoCushion™ Technology.

Key Points: 
  • The Company’s management is excited to meet with many of the 15,000+ participants to introduce its lead product, Spryng™ with OsteoCushion™ Technology.
  • SPRYNG is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • VMX is the largest veterinary conference in the United States and plays host to many of the top industry professionals.

Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions

Retrieved on: 
Thursday, January 11, 2024
Osteoarthritis, Policy, Securities Class Action, Prejudice, Fault, District court, Disclosure, D&O, Security (finance)

The settlements are subject to various conditions, including confirmatory discovery in the Securities Class Action, negotiation and execution of the full settlement agreements and obtaining court approval in each action.

Key Points: 
  • The settlements are subject to various conditions, including confirmatory discovery in the Securities Class Action, negotiation and execution of the full settlement agreements and obtaining court approval in each action.
  • On January 9, 2024, the Company along with the other parties to each case filed status reports in both the Securities Class Action and the Consolidated Derivative Actions, advising the respective courts of the status of the settlements in principle.
  • The settlements in principle do not constitute any admission of fault, wrongdoing or liability as to the Company or any other defendant.
  • The Company has provided disclosure relating to these legal matters in its periodic reports on Forms 10-K and 10-Q throughout the pendency of these actions.

Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

Retrieved on: 
Monday, January 8, 2024
RNA, JW Marriott Hotels, Protein, Neoplasm, Tumor microenvironment, Atherosclerosis, Messenger, WNT16, Aortic aneurysm, SOD2, Tissue, Osteoarthritis, Therapy, DNMT3B, Rheumatoid arthritis, Inflammation, Cancer, Semaphore, Vaccine

HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.

Key Points: 
  • Altamira’s two flagship programs, AM-401 and AM-411, designed for KRAS-driven cancer and rheumatoid arthritis, serve to demonstrate the technology’s capability to enhance therapeutic efficacy
    HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.
  • Covadonga Pañeda, Ph.D., the Company's Chief Operating Officer, will give a presentation at the conference titled, "Delivery of therapeutic RNA in inflammation and cancer using peptide-based nanoparticles”.
  • “However, even the most powerful mRNA therapeutic is useless if it is not delivered safely and effectively into target cells, which has remained one of the key challenges for non-hepatic targets to date.
  • SemaPhore™, Altamira’s peptide-based delivery platform for mRNA, has been successfully tested so far in vivo in models of osteoarthritis (WNT16, DNMT3B), atherosclerosis (p27Kip1), aortic aneurysm (SOD2), and tumor microenvironment (ZBTB46).

New to The Street TV Announces the Interviews of Four Corporate Guest, Episode 541, Airing on Bloomberg TV as Sponsored Programming, Tonight, Thursday, January 4, 2024, 9:30 PM PT

Retrieved on: 
Thursday, January 4, 2024
Magos, Dark, Mastercard, Marketing, AAEP, Osteoarthritis, GOLD, Dasylirion, Worldwide Angel, Lloyd's of London, News, Data mining, Javits Center, Dog, VMX, Sotol, Interview, Web page, Airport, OTCQX, PROMO, Human, Host, Animal, Aircraft, Name, Privacy, Bloomberg Television, IP, Silver, FBI, Horse, Safety, History, Agave, Surf Air Mobility, Cat, ACL, FRA, Internet, OTCQB, Television, Veterinary medicine, Corporation, Theft, Learning, Gold, Air travel, Constitution, Crime, Veterinarian, MGM Resorts International, Cryptocurrency

New to The Street's 541st TV episode line-up features the following Five (5) Corporate interviews:

Key Points: 
  • New to The Street's 541st TV episode line-up features the following Five (5) Corporate interviews:
    1).
  • John informs viewers that the Company was at New York's Javits Convention Center for the 2023 United States Vet Show .
  • From the Nasdaq MarketSite Studio , New to Street features its newest TV business segment, "Money Makers," with TV Co-Hosts Colin Jordon and Jane King.
  • Viewers, please tune in next time for the newest cybersecurity topic on the "Sekur Privacy & Sekur Security– Weekly Hack" segment.

PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH COVETRUS NORTH AMERICA, LLC

Retrieved on: 
Friday, December 22, 2023
Marketing, Osteoarthritis, Animal, Joint, Veterinarian, Patient, Therapy, Arthralgia

MINNEAPOLIS, Dec. 22, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine and companion animals, announced today it has entered into a definitive distribution agreement with Covetrus North America, LLC (“Covetrus”).

Key Points: 
  • MINNEAPOLIS, Dec. 22, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine and companion animals, announced today it has entered into a definitive distribution agreement with Covetrus North America, LLC (“Covetrus”).
  • Covetrus will inventory, market and promote PetVivo’s veterinary medical device, Spryng™ with OsteoCushion™ technology, throughout the United States.
  • "We are incredibly pleased to add Covetrus to our current distribution network to distribute our signature product, Spryng with OsteoCushion technology.
  • For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact [email protected] or visit https://petvivo.com/ and https://sprynghealth.com/ .

End of Year Message From the Chairman of the Board of BioElectronics

Retrieved on: 
Friday, December 22, 2023
Thumb, Veterinary medicine, CIS, Research, FDA, Chronic pain, Phantom limb, Paper, Osteoarthritis, DTR, Stanford University, Dog, University, UCSD, Social media, Bioelectronics, BIEL, Growth, OTC, News

FREDERICK, MD, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corp. (OTC: BIEL) is pleased to provide this end of year message to investors, customers, suppliers and other partners.

Key Points: 
  • FREDERICK, MD, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corp. (OTC: BIEL) is pleased to provide this end of year message to investors, customers, suppliers and other partners.
  • All indications are that the results are very positive, but they are embargoed until they appear in press.
  • If this paper is published, we plan to start actively marketing our RecoveryRx line into the veterinary market.
  • On a more positive note, BioElectronics would like to extend Season Greetings to all its customers and loyal shareholders.

PetVivo Holdings, Inc. Achieves Distribution Milestone Surpassing 4500 Syringes of Spryng™ in 2023

Retrieved on: 
Thursday, December 21, 2023
Ethos, Conference, Syringe, Osteoarthritis, Trial of the century, Animal, Joint, Veterinarian, Therapy, Arthralgia, Pharmaceutical industry

MINNEAPOLIS, MN, US, Dec. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – surpassing 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year.

Key Points: 
  • MINNEAPOLIS, MN, US, Dec. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – surpassing 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year.
  • The distribution of syringes of Spryng is an increase in excess of sixty percent from the previous year.
  • SPRYNG™ with OsteoCushion™ Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.
  • For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact [email protected] or visit https://petvivo.com/ and https://sprynghealth.com/ .